In acute leukemias, VE-822 treatment resulted in reduced output from both RNR and deoxycytidine kinase (dCK) pathways of deoxynucleotide synthesis in ALL cells, with the combination of VE-822 with RNR and dCK inhibition (with 3-AP and DI-82, respectively) being lethal (44). The gene discussed is DCK; the disease is acute leukemia.